|
PT1020454E
(pt)
|
1998-06-19 |
2009-12-21 |
Teijin Pharma Ltd |
Modificações polimórficas do ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazole-carboxílico e processos para a sua preparação
|
|
CA2453182A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Meredith L. Greene |
Crystalline thiazine oxazolidinones
|
|
EP1419151B1
(en)
*
|
2001-08-15 |
2014-02-26 |
Pharmacia & Upjohn Company LLC |
Chrystals including a malic acid salt of n-[2-(diethylamino)ethyl] -5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl] -2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
|
|
CA2471144C
(en)
*
|
2002-01-09 |
2011-06-07 |
Emisphere Technologies, Inc. |
Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
|
|
JP2003261548A
(ja)
*
|
2002-03-07 |
2003-09-19 |
Teijin Ltd |
２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
|
|
WO2003082279A1
(fr)
*
|
2002-03-28 |
2003-10-09 |
Teijin Limited |
Preparation solide contenant une forme monocristalline
|
|
US8841333B2
(en)
*
|
2005-05-09 |
2014-09-23 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for treating nephrolithiasis
|
|
CN100430055C
(zh)
*
|
2005-11-11 |
2008-11-05 |
天津泰普药品科技发展有限公司 |
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
|
|
WO2007148787A1
(ja)
|
2006-06-23 |
2007-12-27 |
Teijin Pharma Limited |
２－（３－シアノ－４－イソブチルオキシフェニル）－４－メチル－５－チアゾールカルボン酸の結晶多形体の製造方法
|
|
CN101139325B
(zh)
*
|
2006-09-07 |
2010-05-12 |
上海医药工业研究院 |
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
|
|
CN101812035B
(zh)
*
|
2006-09-07 |
2012-03-21 |
上海医药工业研究院 |
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
|
|
US20090124623A1
(en)
*
|
2006-11-13 |
2009-05-14 |
Christopher Lademacher |
Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
|
|
US20080269226A1
(en)
*
|
2006-11-13 |
2008-10-30 |
Christopher Lademacher |
Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors
|
|
CN1970547B
(zh)
*
|
2006-12-07 |
2011-04-06 |
重庆医药工业研究院有限责任公司 |
非布司他的晶型及其制备方法
|
|
CN102093309B
(zh)
*
|
2006-12-07 |
2012-07-04 |
重庆医药工业研究院有限责任公司 |
非布司他的晶型及其制备方法
|
|
CN102093308B
(zh)
*
|
2006-12-07 |
2012-08-29 |
重庆医药工业研究院有限责任公司 |
非布司他的晶型及其制备方法
|
|
US20090042887A1
(en)
*
|
2007-01-19 |
2009-02-12 |
Tap Pharmaceutical Products, Inc. |
Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
|
|
CN101412700B
(zh)
*
|
2007-10-19 |
2011-06-08 |
上海医药工业研究院 |
非布司他的晶型及其制备方法
|
|
CN101386605B
(zh)
*
|
2008-10-23 |
2010-09-08 |
中国科学院上海药物研究所 |
非布司他新型晶体及其制备方法
|
|
CN101759656B
(zh)
*
|
2008-12-12 |
2013-04-03 |
重庆医药工业研究院有限责任公司 |
非布司他新晶型及其制备方法
|
|
CN101768150B
(zh)
*
|
2009-01-05 |
2014-08-06 |
常州市第四制药厂有限公司 |
2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
|
|
US20100311756A1
(en)
*
|
2009-01-22 |
2010-12-09 |
Takeda Pharmaceuticals North America, Inc. |
Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
|
|
CN101891702B
(zh)
*
|
2009-05-22 |
2012-07-04 |
重庆圣华曦药业股份有限公司 |
非布司他的晶体、制备方法及在药物中的应用
|
|
CN102803240A
(zh)
|
2009-06-10 |
2012-11-28 |
特瓦制药工业有限公司 |
非布索坦的晶形
|
|
MX2011013946A
(es)
*
|
2009-07-15 |
2012-01-25 |
Teijin Pharma Ltd |
Proceso para producir cristales de acido 2 - 3(3 - ciano - 4 - isobutiloxifenil) - 4 - metil - 5 - tiazolcarboxilico polimorfico mediante el metodo de adicion de solvente deficiente.
|
|
JP5519201B2
(ja)
*
|
2009-07-15 |
2014-06-11 |
光孝 北村 |
２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
|
|
CN103936689B
(zh)
*
|
2009-07-17 |
2016-08-17 |
北京利乐生制药科技有限公司 |
2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
|
|
WO2011080651A2
(en)
|
2009-12-31 |
2011-07-07 |
Ranbaxy Laboratories Limited |
Polymorphic forms of febuxostat
|
|
US20130190366A1
(en)
|
2010-02-19 |
2013-07-25 |
Cadila Healthcare Limited |
Substantially pure salts of febuxostat and processes for preparation thereof
|
|
AU2011222462A1
(en)
|
2010-03-04 |
2012-09-27 |
Ranbaxy Laboratories Limited |
Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
|
|
WO2011134101A1
(zh)
*
|
2010-04-27 |
2011-11-03 |
上海凯米侬医药科技有限公司 |
一种非布索坦的新晶型n及其制备方法
|
|
CN101824005B
(zh)
*
|
2010-04-27 |
2012-06-27 |
上海凯米侬医药科技有限公司 |
一种非布索坦的晶型q及其制备方法
|
|
WO2011139886A2
(en)
*
|
2010-04-29 |
2011-11-10 |
Dr. Reddy's Laboratories Ltd. |
Preparation of febuxostat
|
|
IT1400311B1
(it)
|
2010-05-10 |
2013-05-24 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
|
|
IT1400309B1
(it)
|
2010-05-10 |
2013-05-24 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
|
|
IT1400609B1
(it)
|
2010-05-10 |
2013-06-14 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e metformina e loro uso.
|
|
IT1400310B1
(it)
|
2010-05-10 |
2013-05-24 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e statine e loro uso.
|
|
EP2399911B1
(en)
|
2010-06-25 |
2015-08-19 |
Sandoz Ag |
Polymorphs of Febuxostat
|
|
TW201217347A
(en)
*
|
2010-07-13 |
2012-05-01 |
Interquim Sa |
Process for preparing the crystalline form a of febuxostat
|
|
WO2012020272A2
(en)
|
2010-08-13 |
2012-02-16 |
EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság |
New salts, polymorphs and solvates of a pharmaceutical active ingredient
|
|
EP2613780B1
(en)
|
2010-09-10 |
2014-11-12 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for concomitant treatment of theophylline and febuxostat
|
|
EP2619191A4
(en)
*
|
2010-09-24 |
2014-03-26 |
Hetero Research Foundation |
NEW POLYMORPHS OF FEBUXOSTAT
|
|
CN102442971B
(zh)
*
|
2010-10-13 |
2014-06-18 |
欣凯医药化工中间体（上海）有限公司 |
非布司他的晶型及其制备方法
|
|
WO2012048861A1
(en)
|
2010-10-14 |
2012-04-19 |
Gador S.A. |
A novel febuxostat crystalline form and the process for the preparation thereof
|
|
WO2012056442A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Mapi Pharma Holdings (Cyprus) Limited |
Polymorphs of febuxostat
|
|
TWI590821B
(zh)
*
|
2011-01-18 |
2017-07-11 |
輝瑞有限公司 |
固體分子分散液
|
|
CN102127033A
(zh)
*
|
2011-01-21 |
2011-07-20 |
北京虹湾医药技术有限公司 |
非布索坦晶型及其工业化制备方法
|
|
EP2502920A1
(en)
|
2011-03-25 |
2012-09-26 |
Sandoz Ag |
Crystallization process of Febuxostat from A
|
|
WO2012131590A1
(en)
|
2011-03-31 |
2012-10-04 |
Sandoz Ag |
An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof
|
|
CA2833101A1
(en)
|
2011-04-15 |
2012-10-18 |
Poonam KAUSHIK |
Febuxostat solid dispersion
|
|
WO2012153313A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition of febuxostat
|
|
US20140112992A1
(en)
*
|
2011-06-06 |
2014-04-24 |
Hetero Research Foundation |
Process for febuxostat
|
|
WO2012172461A1
(en)
|
2011-06-13 |
2012-12-20 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of febuxostat
|
|
CA2855923A1
(en)
|
2011-11-15 |
2013-05-30 |
Mylan Laboratories Ltd |
Process for the preparation of febuxostat polymorphs
|
|
WO2013088449A1
(en)
|
2011-12-16 |
2013-06-20 |
Natco Pharma Limited |
Stable crystal form of febuxostat and process for the preparation thereof
|
|
EP2925306A1
(en)
|
2012-07-12 |
2015-10-07 |
Alembic Pharmaceuticals Limited |
Pharmaceutical composition of febuxostat
|
|
EP2692342A1
(en)
|
2012-07-30 |
2014-02-05 |
Interquim, S.A. |
Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
|
|
WO2014057461A1
(en)
|
2012-10-11 |
2014-04-17 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form g of febuxostat
|
|
CN103936688A
(zh)
*
|
2013-01-21 |
2014-07-23 |
上海华拓医药科技发展股份有限公司 |
2-(3-氰基-4-(2-甲基丙氧基)苯基)-4-甲基-5-噻唑甲酸a晶的制备方法
|
|
NO2980085T3
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
2013-03-29 |
2018-08-11 |
|
|
|
CN103396378B
(zh)
*
|
2013-07-29 |
2015-06-10 |
杭州朱养心药业有限公司 |
非布司他结晶
|
|
CN103588724B
(zh)
*
|
2013-09-10 |
2015-05-20 |
杭州华东医药集团新药研究院有限公司 |
一种非布司他晶型a及其制备方法
|
|
JP6283371B2
(ja)
*
|
2013-10-22 |
2018-02-21 |
日本ケミファ株式会社 |
２−［３−シアノ−４−（２−メチルプロポキシ）フェニル］−４−メチルチアゾール−５−カルボン酸の小型化結晶、その微粉化物及びこれらを含有する固形製剤
|
|
EP2881116A1
(en)
|
2013-12-05 |
2015-06-10 |
Ranbaxy Laboratories Limited |
Febuxostat composition
|
|
EP2902016A1
(en)
|
2014-01-30 |
2015-08-05 |
Alfred E. Tiefenbacher (GmbH & Co. KG) |
Febuxostat tablet
|
|
CN103739568B
(zh)
*
|
2014-02-07 |
2015-09-16 |
浙江普洛康裕制药有限公司 |
2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法
|
|
ME03319B
(me)
|
2014-07-30 |
2019-10-20 |
Teijin Pharma Ltd |
Derivat azol benzena i njegov kristal
|
|
EP3002006A1
(en)
|
2014-10-01 |
2016-04-06 |
Bluepharma - Industria Farmacêutica, S.A. |
Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A
|
|
CZ27857U1
(cs)
|
2014-12-12 |
2015-02-23 |
Zentiva, K.S. |
Formulace obsahující tuhý roztok febuxostatu
|
|
JP2016150917A
(ja)
*
|
2015-02-17 |
2016-08-22 |
株式会社トクヤマ |
バルサルタンの結晶の製造方法
|
|
JP7164926B2
(ja)
*
|
2015-04-22 |
2022-11-02 |
日本ケミファ株式会社 |
２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の結晶、その製造方法、及びそれらの利用
|
|
EP3153158A1
(de)
|
2015-10-09 |
2017-04-12 |
Stada Arzneimittel Ag |
Orale febuxostat-tablette
|
|
CN107540630A
(zh)
*
|
2016-06-29 |
2018-01-05 |
康普药业股份有限公司 |
一种非布司他化合物及制备方法
|
|
GR1009119B
(el)
|
2016-06-30 |
2017-09-18 |
"Φαρματεν Α.Β.Ε.Ε." |
Φαρμακευτικο σκευασμα περιεχον ενα μη πουρινικο επιλεκτικο αναστολεα της οξειδασης της ξανθινης και μεθοδος παρασκευης αυτου
|
|
KR20180013563A
(ko)
*
|
2016-07-29 |
2018-02-07 |
한미정밀화학주식회사 |
고순도 결정형 페북소스타트의 개선된 제조 방법
|
|
CN106565627B
(zh)
*
|
2016-10-10 |
2020-01-10 |
扬子江药业集团有限公司 |
一种非布司他药用晶型的制备方法
|
|
GR1009659B
(el)
|
2018-09-07 |
2019-11-28 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει ενα συμπλοκο αλατος της φεβουξοστατης με οξειδιο του μαγνησιου και μεθοδος για την παρασκευη αυτου
|
|
US11498893B2
(en)
|
2018-09-28 |
2022-11-15 |
Kaneka Corporation |
Production method for crystal of reduced coenzyme Q10 having excellent stability
|
|
CN112390766B
(zh)
*
|
2019-08-13 |
2022-09-06 |
浙江天宇药业股份有限公司 |
一种非布司他a晶型的制备方法
|
|
CN111004191A
(zh)
*
|
2019-10-24 |
2020-04-14 |
武汉光谷亚太医药研究院有限公司 |
一种大粒径非布司他a晶的制备方法
|
|
JP7506475B2
(ja)
*
|
2019-12-26 |
2024-06-26 |
東和薬品株式会社 |
フェブキソスタット製剤
|